LONDON, Nov. 28, 2017 /PRNewswire/ — There are various options available to EU5 oncologists and haematologists to treat chronic lymphocytic leukaemia (CLL). Clearly some of these options are achieving greater levels of loyalty and satisfaction than others but why? What are the key factors driving physician choice and how does each of the leading brands compare to its competitors?
Download the full report: https://www.reportbuyer.com/product/5214596
NPS+ CLL (EU5) gives a unique insight into the overall brand health of 6 leading treatments for CLL currently being used in the EU5 markets. 150 oncologists and haematologists were surveyed on key issues including brand messaging, prescribing behaviour and satisfaction levels. The results provide valuable insight for brand marketers seeking new ways to stand out.
Six brands surveyed, five positive NPS. In Europe, 5 of the 6 brands surveyed obtained positive brand health scores, but 1 didn’t. Is it your brand languishing at the bottom of the table, and what could you do about it?
High loyalty for one brand, not so much for the others. Loyalty scores of less than 3 indicate low loyalty, and only one brand manages to score above this magic number. Is clinical differentiation really that low, or does the leading brand really offer something that the others canâ€™t?
Satisfaction high, but this is shared across multiple brands. Unlike US physicians, EU5 physicians are very satisfied with current treatment options. The only issue? This satisfaction is shared across multiple brands.
Is there a dominant brand message? Find out which messages are resonating with physicians, and take your brandâ€™s positioning strategy to another level.
In their own words. What do doctors say each brand means to them? For example, which brand is described as â€œthe immediate future, a paradigm shift in treatmentâ€ and which brand is dubbed as expensive?
Insight into 6 CLL Treatments
Arzerra (ofatumumab; Novartis)
Gazyvaro (obinutuzumab; Roche)
Imbruvica (ibrutinib; AbbVie/Janssen Cilag)
MabThera (rituximab; Roche)
Venclyxto (venetoclax; AbbVie)
Zydelig (idelalisib; Gilead)
Explore Important Brand Loyalty Issues
NPS+ CLL (EU5) offers valuable insight into brand loyalty from the perspective of those currently prescribing treatments for CLL to patients. Youâ€™ll discover:
Exactly how satisfied the European market is.
How loyal doctors are to your brand.
How many other brands your Promoters recommend.
Which other brands your Promoters and Detractors recommend.
How much market share your brand has among Promoters and Detractors.
How much market share you stand to gain by converting Detractors into Promoters.
Which messages Promoters, Passives and Detractors associate with your brand.
Your brand DNA: what doctors really think of your